Very good_老虎社区_美港股上老虎

paulp
2021-06-17

Very good

Raw Material Shortage Holding Up Novavax's COVID-19 Shot Manufacturing, Says Serum Institute

Serum Institute of India (SII) is yet to receive raw materials from the U.S. required to produce the

Raw Material Shortage Holding Up Novavax's COVID-19 Shot Manufacturing, Says Serum Institute

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":161256779,"tweetId":"161256779","gmtCreate":1623930806991,"gmtModify":1634025741528,"author":{"id":3586853657800300,"idStr":"3586853657800300","authorId":3586853657800300,"authorIdStr":"3586853657800300","name":"paulp","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Very good</p></body></html>","htmlText":"<html><head></head><body><p>Very good</p></body></html>","text":"Very good","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/161256779","repostId":1195023201,"repostType":4,"repost":{"id":"1195023201","kind":"news","pubTimestamp":1623930270,"share":"https://www.laohu8.com/m/news/1195023201?lang=&edition=full","pubTime":"2021-06-17 19:44","market":"us","language":"en","title":"Raw Material Shortage Holding Up Novavax's COVID-19 Shot Manufacturing, Says Serum Institute","url":"https://stock-news.laohu8.com/highlight/detail?id=1195023201","media":"benzinga","summary":"Serum Institute of India (SII) is yet to receive raw materials from the U.S. required to produce the","content":"<ul>\n <li>Serum Institute of India (SII) is&nbsp;yet to receive raw materials&nbsp;from the U.S. required to produce the&nbsp;<b>Novavax Inc</b>&nbsp;vaccine despite diplomatic interventions by India, said an official aware of the development.</li>\n <li>The delay in receiving raw materials such as bioreactor bags and enzymes means that SII's launch of the Novavax vaccine, dubbed Covovax in India, will not likely happen before&nbsp;September, as planned initially.</li>\n <li>The company said raw material shortages have led to the delay in launching the vaccine.</li>\n <li>The U.S. lifted the export ban on raw materials on June 4.</li>\n <li>SII is the manufacturing partner for Novavax in India, where the firm has committed to producing up to 1 billion doses.</li>\n <li>Also, the Serum Institute of India plans to start clinical trials of the Novavax shot for children in July, according to&nbsp;ANI quoting sources.</li>\n <li>Earlier this week, NVAX's COVID-19 vaccine&nbsp;demonstrated 90% efficacy.</li>\n <li><b>Price Action:</b>NVAX shares are up 5.9% at $186.68 during the premarket trading session on the last check Thursday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Raw Material Shortage Holding Up Novavax's COVID-19 Shot Manufacturing, Says Serum Institute</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRaw Material Shortage Holding Up Novavax's COVID-19 Shot Manufacturing, Says Serum Institute\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 19:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://wwww.benzinga.com/general/biotech/21/06/21602943/raw-material-shortage-holding-up-novavaxs-covid-19-shot-manufacturing-says-serum-institute><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Serum Institute of India (SII) is yet to receive raw materials from the U.S. required to produce the Novavax Inc vaccine despite diplomatic interventions by India, said an official aware of the ...</p>\n\n<a href=\"https://wwww.benzinga.com/general/biotech/21/06/21602943/raw-material-shortage-holding-up-novavaxs-covid-19-shot-manufacturing-says-serum-institute\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://wwww.benzinga.com/general/biotech/21/06/21602943/raw-material-shortage-holding-up-novavaxs-covid-19-shot-manufacturing-says-serum-institute","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195023201","content_text":"Serum Institute of India (SII) is yet to receive raw materials from the U.S. required to produce the Novavax Inc vaccine despite diplomatic interventions by India, said an official aware of the development.\nThe delay in receiving raw materials such as bioreactor bags and enzymes means that SII's launch of the Novavax vaccine, dubbed Covovax in India, will not likely happen before September, as planned initially.\nThe company said raw material shortages have led to the delay in launching the vaccine.\nThe U.S. lifted the export ban on raw materials on June 4.\nSII is the manufacturing partner for Novavax in India, where the firm has committed to producing up to 1 billion doses.\nAlso, the Serum Institute of India plans to start clinical trials of the Novavax shot for children in July, according to ANI quoting sources.\nEarlier this week, NVAX's COVID-19 vaccine demonstrated 90% efficacy.\nPrice Action:NVAX shares are up 5.9% at $186.68 during the premarket trading session on the last check Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":273,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":8,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}